Study Shows Sanofi Insomnia Drug Works Long-Term
Posted on: Thursday, 13 July 2006, 12:00 CDT
Results from a study show that Sanofi-Aventis' insomnia drug Ambien CR is well-tolerated and effective in improving sleep onset and maintenance for up to six months in patients with chronic primary insomnia.
Patients in the study, who took the drug as needed for up to seven nights per week, did not experience rebound insomnia after treatment with the drug was discontinued.
This evaluation of Ambien CR 12.5mg involved 1,018 adult volunteers who were studied for a period of 25 weeks. The objective was to evaluate the long-term safety and efficacy of Ambien CR taken as needed up to seven nights per week.
According to the data, Ambien CR demonstrated significant improvements in total sleep time, sleep onset latency, wake time after sleep onset, sleep quality, and number of awakenings versus placebo.
"These data are important for patients who experience chronic insomnia because they demonstrate there is a treatment option in Ambien CR that can be taken safely and effectively as needed long-term to help them both fall asleep and maintain sleep through the night," said Dr Tom Roth, director of the Sleep Disorders Center at Henry Ford Hospital.
The data were presented at the Collegium Internationale Neuro-Psychopharmocologicum (CINP) 25th biennial congress in Chicago.
Source: Datamonitor
Related Articles
- Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
- Resolvyx to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting
- Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
- Hollis-Eden Reports Positive Data for Ulcerative Colitis Drug
- N.O. hospitals need patients, money to stay open
- New Orleans Hospitals Need Patients, Money
- The Immune Response Corporation Presents the First Human Data With IR103 at the International AIDS Society Meeting in Rio; REMUNE(R) Data Also Presented in Drug-Naive HIV Positive Individuals
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Adults With Primary Sleep Maintenance Insomnia
 |
 |
User Comments (0)
RSS Feeds